Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
“If my husband leaves me, I will go home and suffer, so better cling to him and hide this thing” The following is a guest post […]
November Moscow conference will inform 2018 United Nations high level meeting When ministers of health and leaders of other government offices and agencies worldwide gather in […]
In the face of a proposal by the Trump administration to cut funding for the National Institutes of Health by nearly a quarter with an $8 […]
The following is a guest post by Courtney Chiaparas for MEASURE Evaluation Malaria disproportionately affects poor, rural populations, with pregnant women and young children at highest risk […]